Clinical trials: Depression / Major Depressive Disorder
Major Depressive Disorder
Stimulant Enhancement of Well-Being Therapy for Depression
This study aims to identify a novel enhancement strategy for residual symptoms of major depressive disorder (MDD) Dopamine (DA) has been viewed as a "pleasure neurotransmitter" for over 30 years.
- Trial name
- NCT01478113
- Testing
- Amphetamine/dextroamphetamine, Well-being therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD.
- Trial name
- B2411003 (NCT00770289)
- Testing
- Cohort
- Where
- 3 sites in Greece
- Volunteers
- 851 people
- Sponsor
- Pfizer
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Reducing Internalized Stigma in People With Serious Mental Illness
The purpose of this study is to determine if Ending Self-Stigma (ESS), a 9-session group intervention designed to assist veterans with serious mental illness to develop skills (SMI) to effectively cope with stigma and minimize…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
- Trial name
- ESS (NCT01259427)
- Testing
- Ending Self Stigma (ESS), Health and Wellness Group
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Electroconvulsive Therapy Amplitude Titration
This study is focused on advancing ECT treatment for older adults with depressive disorders by refining neuromodulation stimulus parameters to improve efficacy and cognitive safety.
- Trial name
- NCT04621786
- Testing
- Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of New Mexico
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen
Major Depressive Disorder
Cysteamine Therapy for Major Depressive Disorder
The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
- Trial name
- NCT00715559
- Testing
- cysteamine bitartrate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
The purpose of this study is to determine the effect of LY2216684 on heart rate and blood pressure in research participants with MDD who are being treated with an SSRI (selective serotonin reuptake inhibitors).
- Trial name
- NCT01263223
- Testing
- LY2216684
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.
- Trial name
- NCT03352453
- Testing
- Rapastinel
- Where
- 17 sites in United States
- Volunteers
- 138 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depression
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
- Trial name
- PROTECT (NCT00536172)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Major Depressive Disorder
Development of Pregnenolone as a Treatment for Depression
Pregnenolone, an over-the-counter supplement, is a naturally occurring neurosteroid made in the adrenal glands and brain. Preclinical research suggests pregnenolone has antidepressant, cognitive enhancing, and neuroprotective…
- Trial name
- NCT03645096
- Testing
- Pregnenolone 500 mg, Pregnenolone 800 mg
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
A Study of LY2216684 and Theophylline in Healthy Subjects
The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme.
- Trial name
- NCT01263106
- Testing
- LY2216684, Theophylline
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depression
Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.
- Trial name
- NCT00834652
- Testing
- Sertraline, Metformin
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Major
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
Study to assess efficacy of Duloxetine 120 mg and Duloxetine 60 mg in patients hospitalized for severe depression after 4 weeks of treatment. To evaluate the rescue option in non-responding patients.
- Trial name
- NCT02229825
- Testing
- Duloxetine
- Volunteers
- 339 people
- Sponsor
- Boehringer Ingelheim
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC
Depression, Alcoholism
Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
We will study patients with a current major depressive episode, comorbid alcoholism and a history of a past suicide attempt. All subjects with alcohol dependence will be evaluated for risk of alcohol withdrawal prior to…
- Conditions
- Depression, Alcoholism, Suicidal Behavior
- Trial name
- NCT00449007
- Testing
- fluoxetine, bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.
- Trial name
- NCT04476030
- Testing
- SAGE-217, Sertraline, Escitalopram
- Where
- 51 sites in United States
- Volunteers
- 440 people
- Sponsor
- Biogen
Major Depressive Disorder
A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
This study is a retrospective database study in Japan to evaluate the relative risk of serious intracranial hemorrhage requiring hospitalization between Vortioxetine tablet treatment and selective serotonin reuptake inhibitor…
- Trial name
- NCT05932407
- Testing
- Vortioxetine Tablet, SSRI
- Where
- Japan
- Volunteers
- 147,777 people
- Sponsor
- Takeda
Major Depressive Disorder
Brain Connectivity and Response to Tai Chi in Geriatric Depression
The purpose of this study is to evaluate the effects after up to 1 year of supervised weekly Tai-Chi-Chi versus Health Education and Wellness classes on reduction of depressive symptoms and improvement in resilience, health…
- Trial name
- NCT02460666
- Testing
- Tai-Chi-Chih (TCC), Health Education and Wellness Classes (HEW)
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder (MDD)
A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder
The purpose of this study is to assess nausea severity in response to four different drug dosing strategies of Duloxetine (30 mg with food, 60 mg with food, 30 mg without food, and 60 mg without food) in Korean patients with…
- Trial name
- NCT00960986
- Testing
- Duloxetine hydrochloride
- Where
- 7 sites in South Korea
- Volunteers
- 249 people
- Sponsor
- Eli Lilly and Company